These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17522532)

  • 1. Recombinant human activated protein C sentenced to the death of a thousand cuts?
    O'Brien JM
    Crit Care Med; 2007 Jun; 35(6):1609-10. PubMed ID: 17522532
    [No Abstract]   [Full Text] [Related]  

  • 2. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 3. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 5. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Rustige J
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698; author reply 1699-70. PubMed ID: 15273923
    [No Abstract]   [Full Text] [Related]  

  • 6. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise.
    Carlet J
    Crit Care Med; 2006 Feb; 34(2):525-9. PubMed ID: 16424736
    [No Abstract]   [Full Text] [Related]  

  • 8. Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial.
    Farmer JC
    Crit Care Med; 2005 Oct; 33(10):2428-31. PubMed ID: 16215411
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe sepsis and therapy with activated protein C.
    Parrillo JE
    N Engl J Med; 2005 Sep; 353(13):1398-400. PubMed ID: 16192486
    [No Abstract]   [Full Text] [Related]  

  • 10. Drotrecogin alfa: excess mortality in the least severely ill patients.
    Prescrire Int; 2005 Aug; 14(78):145. PubMed ID: 16108104
    [No Abstract]   [Full Text] [Related]  

  • 11. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 12. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database.
    de Pont AC; Bakx R; Boermeester MA; Schultz MJ
    Surgery; 2007 Jun; 141(6):828-9. PubMed ID: 17560262
    [No Abstract]   [Full Text] [Related]  

  • 14. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 15. The efficacy of drotrecogin alfa depends on severity of illness.
    Deans KJ; Minneci PC; Eichacker PQ; Natanson C
    Crit Care Med; 2004 Nov; 32(11):2347. PubMed ID: 15640655
    [No Abstract]   [Full Text] [Related]  

  • 16. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 17. Treating sepsis.
    Wenzel RP
    N Engl J Med; 2002 Sep; 347(13):966-7. PubMed ID: 12324551
    [No Abstract]   [Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
    Friedrich JO; Adhikari NK; Meade MO
    Crit Care; 2006; 10(6):427. PubMed ID: 17214908
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of sepsis.
    Mackenzie AF; Bartelink AK
    N Engl J Med; 2007 Mar; 356(11):1179; author reply 1181-2. PubMed ID: 17361493
    [No Abstract]   [Full Text] [Related]  

  • 20. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.